Hubbry Logo
Involution (medicine)Involution (medicine)Main
Open search
Involution (medicine)
Community hub
Involution (medicine)
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Involution (medicine)
Involution (medicine)
Involution (medicine)
View on Wikipedia
from Wikipedia

Involution is the shrinking or return of an organ to a former size. At a cellular level, involution is characterized by the process of proteolysis of the basement membrane (basal lamina), leading to epithelial regression and apoptosis, with accompanying stromal fibrosis. The consequent reduction in cell number and reorganization of stromal tissue leads to the reduction in the size of the organ.

Examples

[edit]

Thymus

[edit]

The thymus continues to grow between birth and sexual maturity and then begins to atrophy, a process directed by the high levels of circulating sex hormones. Proportional to thymic size, thymic activity (T cell output) is most active before maturity. Upon atrophy, the size and activity are dramatically reduced, and the organ is primarily replaced with fat. The atrophy is due to the increased circulating level of sex hormones, and chemical or physical castration of an adult results in the thymus increasing in size and activity.[1]

Uterus

[edit]

Involution is the process by which the uterus is transformed from pregnant to non-pregnant state. This period is characterized by the restoration of ovarian function in order to prepare the body for a new pregnancy. It is a physiological process occurring after parturition; the hypertrophy of the uterus has to be undone since it does not need to house the fetus anymore. This process is primarily due to the hormone oxytocin. The completion of this period is defined as when the diameter of the uterus returns to the size it is normally during a woman's menstrual cycle.[citation needed]

Mammary gland

[edit]

During pregnancy until after birth, mammary glands grow steadily to a size required for optimal milk production. At the end of nursing, the number of cells in the mammary gland becomes reduced until approximately the same number is reached as before the start of pregnancy.

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Involution (medicine)

View on Grokipedia
from Grokipedia
Involution in refers to the retrograde shrinking or return of an organ or tissue to its pre-enlarged state following a period of , often characterized by cellular degeneration, , and tissue remodeling. This physiological process is essential for restoring normal and function after events such as , , or aging. At the cellular level, involution typically involves (), reorganization, and immune-mediated clearance of superfluous cells. One of the most prominent examples is uterine involution, which occurs postpartum as the contracts from approximately 1 kg to 50-70 grams within six weeks, expelling and reverting dilated arteries to spiral forms. Failure of this process, known as subinvolution, can lead to complications like secondary postpartum hemorrhage, which affects about 1% of deliveries. Similarly, involution follows or cessation, reducing epithelial cell mass through , with abrupt cessation potentially elevating risk via the "involution hypothesis." Another key instance is , an age-related regression of the gland starting in and progressing over decades, resulting in reduced T-cell production and contributing to . Beyond these, involution manifests in other contexts, such as the corpus luteum's atrophy post-implantation or general senile changes in aging tissues, underscoring its role in both normal development and pathological states. Disruptions in involution can exacerbate conditions like infections or malignancies, highlighting its clinical significance in reproductive health, , and .

Definition and Types

General Definition

Involution in refers to the progressive shrinkage, degeneration, or return of an organ or tissue to its pre-growth or normal size following a period of enlargement or hyperactivity, typically involving a reduction in cell number or size. This process represents a retrogressive change in vital functions after they have been fulfilled, such as the restoration of tissues to a baseline state post-stimulation. The term originates from the Latin involūtiō, meaning "a rolling up" or "envelopment," which evokes the inward contraction and enfolding observed during the tissue regression. This etymology underscores the organized inward remodeling inherent to the . Involution differs from , an increase in organ size due to enlarged cell volume often from sustained , and from , a nonspecific wasting of tissues due to disuse, , or disease that lacks programmed coordination. Instead, involution is distinguished by its physiological, programmed progression, as seen briefly in postpartum uterine restoration. At the cellular level, involution features hallmarks such as of the to facilitate structural collapse and cell death primarily driven by , ensuring controlled tissue regression without .

Physiological Involution

Physiological involution represents a normal, adaptive characterized by the progressive reduction in size and cellularity of organs or tissues after they have reached a functional peak or undergone temporary expansion in response to developmental cues. This regression involves coordinated cellular remodeling, including and reorganization, to restore the tissue to its baseline state without compromising overall organismal health. In the context of development, physiological involution occurs post-maturity or following the cessation of heightened activity, such as after reproductive events, enabling organs to downscale once their primary role concludes and reallocating physiological resources efficiently. It contributes to long-term developmental progression by preventing sustained , which could otherwise lead to inefficient energy use or structural imbalances. The adaptive benefits of this process include conservation of metabolic resources, maintenance of systemic , and facilitation of cyclic physiological functions, such as repeated reproductive cycles in mammals. By clearing excess or functionally obsolete cells, involution minimizes the risk of aberrant growth and supports the body's ability to respond to future demands. Typically, physiological involution unfolds gradually over a timeline ranging from days to years, depending on the tissue involved, and is often permanent, though partial reversibility can occur in response to renewed stimuli in certain contexts. Hormonally, it is primarily triggered by the withdrawal of key growth-promoting factors, such as estrogen or prolactin, which shifts signaling toward regressive pathways and initiates the involutive cascade.

Pathological Involution

Pathological involution refers to the dysregulated or abnormal execution of physiologic involution processes due to , , or other stressors, leading to excessive, untimely, or impaired tissue regression and potential functional impairment. Unlike normal involution, this form involves disrupted coordination of cell loss, often through exacerbated or . Common triggers include acute stressors such as severe infections or exposure, which accelerate apoptotic pathways beyond adaptive levels. These culminate in disproportionate tissue loss, distinguishing pathological from adaptive responses. Key characteristics encompass disorganized tissue shrinkage, potentially accompanied by , and the process is often irreversible due to impaired regeneration. In affected tissues, this manifests as altered architecture with excessive cell clearance replacing functional elements. Examples include acute thymic involution induced by infections or corticosteroids, which rapidly depletes lymphoid tissue through glucocorticoid-mediated . These instances highlight how stressors can precipitate non-physiological tissue decline. typically involves imaging modalities like computed tomography (CT) or (MRI) to detect organ size reduction, alongside analysis that reveals elevated markers—such as fragmented DNA or activation—without evidence of compensatory regeneration or . These indicators help differentiate pathological involution from reversible conditions.

Mechanisms of Involution

Cellular Processes

In physiological involution, the primary cellular mechanism driving tissue regression is apoptosis, a form of programmed cell death that systematically eliminates superfluous cells while minimizing inflammation to surrounding tissues. This process is initiated by extrinsic or intrinsic signals that activate initiator caspases, such as caspase-8 or caspase-9, which in turn cleave and activate executioner caspases like caspase-3 and caspase-7. These effector caspases orchestrate key morphological changes, including cytoplasmic shrinkage, chromatin condensation, and DNA fragmentation into nucleosomal units, ultimately leading to the formation of apoptotic bodies. Epithelial cells are particularly susceptible during involution, often undergoing anoikis—a specialized form of apoptosis triggered by detachment from the extracellular matrix and loss of integrin-mediated survival signals—which prevents ectopic cell survival and maintains tissue architecture. In contrast, stromal cells, including fibroblasts and adipocytes, primarily contribute to remodeling rather than widespread death, facilitating the reorganization of the tissue scaffold through proteolytic activities. Secondary processes complement apoptosis to ensure efficient tissue regression. Autophagy degrades intracellular components, such as damaged organelles and protein aggregates, via lysosome fusion, providing an alternative or supportive pathway for cellular dismantling in certain contexts. Additionally, proteolysis by matrix metalloproteinases (MMPs), such as MMP-3 and MMP-9, remodels the by breaking down and other structural proteins, enabling the collapse and resorption of the tissue framework. The sequence of cellular events in involution typically unfolds in phases: by withdrawal of signals (including brief hormonal cues), followed by the execution phase marked by caspase-mediated cell dismantling and shrinkage, and culminating in clearance where apoptotic bodies are phagocytosed by resident macrophages or neighboring cells to prevent secondary . This orchestrated progression ensures orderly tissue reduction without disrupting adjacent structures.

Molecular and Hormonal Regulation

Molecular and hormonal regulation of involution involves coordinated signaling pathways and endocrine shifts that trigger tissue regression, primarily through the promotion of and inhibition of cell survival mechanisms. Key among these is the transforming growth factor-β (TGF-β) signaling pathway, which drives epithelial cell regression by activating downstream effectors that induce and remodeling. In involution, TGF-β ligands, particularly TGF-β1 and TGF-β3, are upregulated following , leading to Smad-dependent transcription of pro-apoptotic genes and suppression of proliferative signals; this process is essential for dismantling alveolar structures and has been modeled as a for studying TGF-β's role in tissue . Similarly, in , TGF-β signaling in epithelial cells directly impairs thymopoiesis by altering the stromal microenvironment, thereby contributing to age-related T-cell decline. Deactivation of signal transducer and activator of transcription (STAT) proteins represents another pivotal regulatory switch, particularly in post-lactational contexts. During lactation, STAT5 activation by sustains mammary epithelial survival and differentiation, but its rapid deactivation upon withdrawal permits activation, which orchestrates lysosomal-mediated and tissue remodeling. 's tyrosine phosphorylation peaks early in involution, promoting the expression of death effectors while suppressing survival pathways, and its inhibition delays regression, underscoring its non-redundant role. This reciprocal /STAT5 dynamic ensures a controlled transition from proliferation to regression, with implications for understanding reversible tissue states. Hormonal changes act as upstream initiators, with withdrawal of supportive steroids and peptides precipitating involution across tissues. In uterine involution, the postpartum decline in and levels removes inhibitory effects on myometrial contraction and epithelial turnover, allowing autolytic processes to proceed; downregulation, in particular, sensitizes the to pro-regressive signals. For mammary tissue, the sharp drop in following suckling cessation disrupts JAK2-STAT5 signaling, thereby unleashing apoptotic cascades that were suppressed during . In the thymus, , such as , mediate acute stress-induced involution by binding glucocorticoid receptors to induce ; their role in chronic age-related involution is more complex and may involve delaying progression in some models. These hormonal shifts create a permissive environment for molecular pathways to execute regression. At the gene expression level, involution is marked by the upregulation of pro-apoptotic members and downregulation of anti-apoptotic counterparts, tilting the balance toward mitochondrial outer membrane permeabilization. Bax and Bim transcripts increase in regressing tissues, facilitating release and activation; for instance, in mammary involution, Bim's BH3-only domain sequesters , amplifying death signals. Conversely, survival factors like are swiftly repressed post-hormone withdrawal, with their high lactation-era expression collapsing to permit widespread epithelial clearance. This Bcl-2 rheostat ensures efficient, non-inflammatory cell elimination. Feedback loops involving further modulate involution's pace and outcome via (NF-κB). In mammary regression, NF-κB activation by local cytokines recruits immune cells, which can accelerate through signaling but may inhibit complete remodeling if chronically engaged, as seen in delayed involution models. This dual role—pro-regressive in acute phases via crosstalk, inhibitory in persistent —highlights NF-κB's context-dependent regulation, integrating immune surveillance with tissue decommissioning.

Examples in Organs and Tissues

Uterine Involution

Uterine involution refers to the postpartum regression of the to its pre-pregnancy size and structure, a critical physiological process that occurs following delivery of the . Immediately after birth, the weighs approximately 1 kg and measures about 20 cm in length and width, but it undergoes rapid contraction and remodeling to reduce to 50-70 g and near its non-pregnant dimensions of 7-8 cm by 6 weeks postpartum. This shrinkage primarily involves myometrial contractions that compress blood vessels to minimize , followed by a reduction in myometrial cell size through autolysis and of decidual and vascular tissues. Concurrently, the undergoes shedding as , characterized by the and sloughing of superficial and basal layers, with regeneration occurring via endometrial stem and progenitor cells that differentiate to restore the functional layer within 2-3 weeks. The timeline of uterine involution features an initial rapid phase from days 1 to 7, during which the uterus decreases to about 500 g and the fundus descends from the umbilicus at a rate of 1-2 cm per day, reaching the by day 10-14. This is followed by a slower remodeling phase extending to 6-8 weeks, involving degradation and tissue reorganization to achieve full restoration. Label-retaining stromal cells, identified as putative mesenchymal stem cells, play a key role in this regeneration by awakening from quiescence during early involution to contribute to endometrial repair. Bone marrow-derived progenitor cells also support this process, aiding in the remodeling of the uterine tissue without . Hormonal changes drive uterine involution, with oxytocin released from the —particularly stimulated by —inducing strong myometrial contractions that facilitate initial shrinkage and expulsion of . The abrupt postpartum decline in and progesterone levels further promotes remodeling by enhancing collagenase activity in the and , leading to tissue breakdown and regeneration. Incomplete uterine involution, known as subinvolution, occurs when the uterus fails to regress adequately, often due to retained placental fragments, , or overstretched from multiple , resulting in prolonged lochia rubra beyond 1 week and secondary postpartum hemorrhage from persistent bleeding at the placental site. This complication is relatively rare (approximately 0.02-0.2% for severe cases associated with subinvolution of the placental site, though overall secondary postpartum hemorrhage incidence is 0.2-2%) and, as of 2025, reports indicate a rising incidence potentially linked to diagnostic or practice changes. It may necessitate interventions such as uterotonics, , or in severe cases to control hemorrhage.

Mammary Gland Involution

Mammary gland involution refers to the regression of breast tissue following the cessation of , during which the expanded alveolar structures that form during and are dismantled to restore a pre--like state dominated by . This process involves the collapse of the alveolar , where secretory epithelial cells undergo and detach, leading to the clearance of milk-filled lumens, followed by the repopulation of adipocytes in the stromal compartment. The structural remodeling is characterized by a reduction in epithelial complexity, with terminal ductal lobular units simplifying and the gland returning to a quiescent, fat-filled morphology. Involution proceeds in two distinct phases: an initial reversible phase dominated by lysosomal-mediated , and a subsequent irreversible phase involving and remodeling. In the first phase, occurring shortly after , epithelial cells experience stasis, triggering lysosomal permeabilization and the release of cathepsins, which initiate cell without full activation, allowing potential reversibility if nursing resumes. This is followed by the second phase, where matrix metalloproteinases degrade the , enabling irreversible tissue restructuring and differentiation to refill the space vacated by dying epithelial cells. The timeline of involution begins rapidly upon , with initial lysosomal-mediated evident within 24 hours, marked by peak epithelial shedding and immune cell infiltration for debris clearance. Major structural changes, including significant reduction in alveolar structures, occur over the first 2-4 weeks, though full restoration to a nulliparous-like state may take 2-3 months in humans, with immune and inflammatory responses subsiding by then. In models, which provide mechanistic insights applicable to humans, the bulk of epithelial regression completes within 6-10 days. Hormonal regulation is pivotal, with the suppression of signaling upon initiating milk stasis and activating local pro-apoptotic factors. Prolactin withdrawal shifts the gland from a proliferative to a regressive state, while local mediators such as insulin-like growth factor binding protein-5 (IGFBP-5) enhance by modulating availability and promoting in the early phase. Additional factors, including tumor necrosis factor-alpha (TNFα) and transforming growth factor-beta 3 (TGF-β3), amplify lysosomal activity and to facilitate tissue clearance. Lobular involution plays a protective role against by substantially reducing the epithelial cell mass, thereby decreasing the pool of cells susceptible to oncogenic transformation. Complete involution, particularly when achieved through gradual processes like prolonged , is associated with a 3-fold lower risk in postmenopausal women compared to those with minimal involution, as it simplifies ductal structures and limits proliferative compartments. This protective effect is evident in parous women, where full regression correlates with reduced incidence, highlighting involution's role in long-term breast tissue .

Thymic Involution

Thymic involution refers to the progressive age-related of the gland, a primary lymphoid organ essential for T-cell maturation. This process involves the shrinkage of both the cortical and medullary compartments, accompanied by the replacement of functional thymic tissue with and the expansion of perivascular spaces. Thymic epithelial cells (TECs), which provide critical structural support for T-cell development, undergo increased , leading to disruption of the thymic stromal microenvironment and a decline in overall thymic cellularity. Fibroblasts and adipocytes proliferate, further contributing to the loss of thymopoietic capacity. The timeline of thymic involution in humans typically begins around , with the reaching peak size in before starting to regress. By age 20, thymic mass has decreased by approximately 50%, and the process accelerates thereafter, resulting in near-complete by age 60, at which point functional thymic tissue constitutes less than 10% of the original volume. The rate of decline is about 3% per year through (up to 35-45 years), slowing to around 1% annually in later decades, ultimately leading to the cessation of significant T-cell output by advanced age. Hormonal factors play a key role in driving this involution. Sex steroids, including androgens and estrogens, promote thymic by inducing in thymocytes and TECs while inhibiting thymopoiesis; for instance, exogenous administration of these hormones can cause rapid thymic collapse. In contrast, (GH) exerts an opposing effect by stimulating TEC proliferation and enhancing T-cell development, though circulating GH levels naturally decline with age, exacerbating the involution. Functionally, thymic involution results in a marked reduction in the production and peripheral emigration of naive T cells, diminishing T-cell repertoire diversity and impairing adaptive immune responses. This contributes to , characterized by increased vulnerability to infections, diminished vaccine efficacy, and a shift toward T-cell dominance, as detailed in broader discussions of aging and immunity.

Other Examples

Corpus luteum involution refers to the regression of the , a temporary endocrine structure in the , following successful implantation of the . Initially formed after to produce progesterone, it undergoes luteolysis post-implantation as the assumes hormone production, involving of luteal cells, vascular regression, and tissue remodeling, typically completing by 8-12 weeks of gestation. Ovarian involution occurs post-menopause, characterized by the progressive depletion of primordial follicles through , where apoptosis spreads to oocytes via gap junctions, leading to a significant reduction in follicle numbers and ovarian size. This process is accompanied by increased stromal , with elevated collagen deposition replacing functional tissue and further impairing ovarian architecture. Consequently, production declines markedly due to the loss of granulosa cells, the primary site of synthesis, resulting in systemic effects such as diminished hormonal activity. In the pineal gland, age-related involution manifests as progressive , with incidence rising from approximately 2% in children aged 0-9 years to over 80% in those above 30 years, primarily composed of deposits that resemble bone formation. This correlates with a decline in synthesis, attributed to reduced β-adrenergic receptor density and diminished expression of the , leading to lower levels and disrupted circadian rhythms. Adrenal cortex involution during senescence involves a gradual reduction in the , evident in individuals over 50 years through histological staining and telomere shortening, alongside overall decreased adrenal weight that peaks in mid-life before declining. Degeneration in this zone is pronounced in senescent models, affecting up to 51% of cells in aged , contributing to altered dynamics. Across these sites, involution shares common reliance on as a core cellular mechanism for tissue remodeling, yet triggers remain site-specific, such as hormonal withdrawal in ovaries versus age-driven calcification in the .

Clinical Significance

In Aging and

In aging, cumulative involution across multiple organ systems contributes to systemic decline, manifesting as in , through imbalanced , and associated with brain volume loss. represents the progressive involution of muscle tissue, characterized by loss of mass and function that impairs mobility and metabolic health in older adults. , often termed involutional osteoporosis, arises from age-related dysregulation of exceeding formation, leading to fragility and increased fracture risk. Similarly, involves gradual shrinkage of brain structures, particularly in the frontal and temporal lobes, correlating with diminished cognitive performance and heightened vulnerability to neurodegeneration. These processes collectively reduce physiological reserve, exacerbating frailty and dependency in . Mechanisms driving involution in aging include shortening, which limits cell replication and accelerates , thereby depleting functional tissue compartments. This attrition activates DNA damage responses that promote , contributing to net tissue regression over time. further exacerbates involution by generating that damage proteins, enhancing through pathways like the ubiquitin-proteasome system to clear aggregates, but ultimately overwhelming clearance capacity and fostering tissue . For instance, age-related exemplifies this, where such mechanisms reduce T-cell production and immune competence. Partial reversibility of involution is achievable in certain tissues through interventions like caloric restriction and exercise, which mitigate underlying molecular drivers. Caloric restriction delays muscle involution by suppressing age-related gene expression changes and enhancing mitochondrial function, thereby preserving mass and strength. Resistance exercise can reverse transcriptomic signatures of aging in , restoring and reducing . From an evolutionary standpoint, these processes reflect programmed , where somatic maintenance is deprioritized in later life to favor earlier , as per the disposable soma theory. This trade-off optimizes fitness in environments with high extrinsic mortality but manifests as involution in prolonged human lifespans.

Relation to Disease and Cancer

Involution processes in various tissues can contribute to pathological conditions, particularly when dysregulated or incomplete, fostering environments conducive to progression. In the mammary gland, postpartum involution promotes metastasis through inflammatory signaling pathways that remodel the and enhance tumor cell dissemination. This phase, occurring after , upregulates proteases and cytokines, creating a pro-tumorigenic microenvironment that increases the risk of metastasis in women diagnosed with within 5-10 years postpartum, with studies showing up to a 2.8-fold elevated risk compared to non-postpartum cases. Incomplete or delayed lobular involution, often observed in aging or parous women, is independently associated with heightened incidence, as it maintains dense stromal tissue that supports , with complete involution linked to reduced risk. Beyond cancer, involution in other organs heightens susceptibility to non-oncologic diseases. Thymic involution diminishes naïve T-cell production and central tolerance, impairing adaptive immunity and elevating risks of infections and autoimmune disorders; for instance, accelerated thymic atrophy correlates with higher incidence of opportunistic infections and conditions like in older adults. Uterine subinvolution, characterized by delayed regression of the placental site, leads to persistent hemorrhage due to incomplete vascular occlusion, often presenting as secondary beyond 24 hours after delivery, and can precipitate or severe infections if untreated. Therapeutic strategies targeting involution hold promise for mitigating these disease risks. In mammary involution, matrix metalloproteinase (MMP) inhibitors, such as those targeting MMP-2 and MMP-9 which are upregulated during tissue remodeling, have shown potential to suppress degradation and reduce tumor promotion in preclinical models, suggesting a role in . For , stem cell-based regenerative approaches, including transplants and pluripotent stem cell-derived thymic organoids, aim to restore T-cell output and immune competence, with early trials demonstrating improved thymopoiesis in aged or immunodeficient models. Ongoing research in the highlights gaps in understanding involution's dual role in parity-related dynamics, where full-term and confer long-term protection via immune priming, yet postpartum involution transiently elevates risk for estrogen receptor-negative subtypes; studies indicate minimal overall protective genetic effects from early parity, underscoring the need for targeted interventions during this window.

References

  1. https://www.rxlist.com/involution/definition.htm
  2. https://www.sciencedirect.com/topics/medicine-and-dentistry/involution
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC400663/
  4. https://my.clevelandclinic.org/health/body/22655-uterus-involution
  5. https://doi.org/10.5858/2006-130-1538-sotpsa
  6. https://www.sciencedirect.com/science/article/pii/S0024320514002914
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9381902/
  8. https://www.oxfordreference.com/display/10.1093/oi/authority.20110803100010461
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC2750859/
  10. https://www.biologyonline.com/dictionary/involution
  11. https://www.tabers.com/tabersonline/view/Tabers-Dictionary/754276/0/involution
  12. https://www.etymonline.com/word/involution
  13. https://www.amboss.com/us/knowledge/cellular-changes-and-adaptive-responses/
  14. https://simplemed.co.uk/subjects/pathology/cellular-adaptations
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2933211/
  16. https://www.sciencedirect.com/topics/immunology-and-microbiology/involution
  17. https://www.ncbi.nlm.nih.gov/books/NBK555904/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC2763512/
  19. https://www.sciencedirect.com/science/article/pii/B978012374407400501X
  20. https://medicine.nus.edu.sg/pathweb/wp-content/uploads/2022/09/Study-notes_Cell-injury-cell-death-and-adaptation.pdf
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC7171462/
  22. https://dspace.vnmu.edu.ua/bitstream/handle/123456789/6345/24-32-PB.pdf?sequence=1&isAllowed=y
  23. https://link.springer.com/article/10.1007/s00005-017-0462-x
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2108307/
  25. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.634690/full
  26. https://www.nature.com/articles/s41418-017-0012-4
  27. https://www.ahajournals.org/doi/10.1161/01.atv.0000099882.52647.e4
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC1557708/
  29. https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr307
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC2797127/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC5294963/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC2481556/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC3732813/
  34. https://www.mdpi.com/1422-0067/19/6/1695
  35. https://www.sciencedirect.com/science/article/pii/S0012160618302677
  36. https://www.sciencedirect.com/science/article/abs/pii/0093691X96001227
  37. https://pubmed.ncbi.nlm.nih.gov/9854140/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC2736092/
  39. https://www.oncotarget.com/article/2792/text/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC1170389/
  41. https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr1401
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4356241/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC9313624/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC7872918/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC8887715/
  46. https://blog.thesullivangroup.com/understanding-secondary-postpartum-hemorrhage
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC12365341/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4306139/
  49. https://www.nature.com/articles/s41523-020-00196-3
  50. https://pubmed.ncbi.nlm.nih.gov/12538768/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC2693781/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3888478/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3375084/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC6971920/
  55. https://www.sciencedirect.com/topics/medicine-and-dentistry/luteolysis
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC10956231/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC6017004/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC10410302/
  59. https://pubmed.ncbi.nlm.nih.gov/4561027/
  60. https://doi.org/10.3390/proteomes10030029
  61. https://doi.org/10.3389/fragi.2022.927630
  62. https://doi.org/10.1113/JP270543
  63. https://doi.org/10.1111/j.1365-2796.2007.01901.x
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC8285071/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC4363120/
  66. https://www.sciencedirect.com/science/article/abs/pii/S1877782120300199
  67. https://academic.oup.com/jnci/article/98/22/1600/2521878
  68. https://www.nejm.org/doi/full/10.1056/NEJMoa2302892
  69. https://meridian.allenpress.com/aplm/article/130/10/1538/459695/Subinvolution-of-the-Placental-Site-as-an-Anatomic
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC8113939/
  71. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00093-6
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC12487161/
  73. https://pubmed.ncbi.nlm.nih.gov/41115453/
Add your contribution
Related Hubs
User Avatar
No comments yet.